secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000899923-23-000008
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q4 revenue $177.8M (+11% YoY); GAAP EPS $(0.52), adjusted EPS $(0.12)
--------------------------------------------------------------------------------

- Q4 testing volumes up 26% YoY; hereditary cancer +16%, GeneSight +23%.
- Full-year 2022 GeneSight revenue grew 36% to $127.6M.
- FY2023 guidance: revenue $720-750M, adjusted EPS $(0.40)-$(0.20).
- Q1 2023 guidance: revenue $170-172M, adjusted EPS $(0.20)-$(0.18).
- Ended Q4 with $169.7M cash, no debt; cash used in ops $7.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000008/0000899923-23-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000008/mygn-20230228.htm
  HTML page:      https://secwatch.observer/filing/0000899923-23-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer